A multicentre study on 89SrCl2 therapy in patients with painful bone metastases

Objective: The aim of the study was to systematically compare the efficacy, toxicity of 89SrCl2 produced domestically (Chengdu Gaotong Isotope Cooperation) with Metastron (Amersham) in palliation of painful skeletal metastases. Methods: A multicenter clinical study was conducted during August 2004 to March 2005. Five Nuclear Medicine Departments participated. Ninety-four of 95 patients were treated with a single intravenous dose (148 MBq) of 89SRCl2, 30 received Metastron(group A) and 64 domestic product, the results could be evaluated. Patients were followed up for a period of 3 months. The results as pain relief and consumption of analgesic drugs, were expressed at four levels: 1, no response; 2, mild response; 3, good response; 4, excellent response. Results: There was no difference in general information, physical strength, grades and positions of ache, compliance, security and use of drug between groups A and B. In per protocol set (PPS) group, response rate in group A was 66.67%, in group B 71.43%, with no significant difference between two groups. In full analysis set (FAS), response in group A and B was 66.67% and 70.31%, respectively. Haematological toxicity mainly affected PLT and WBC, with no significant difference between two groups. Conclusion: Good pain palliation in patients with bone metastases could be achieved with 89SrCl2, whether produced domestically or imported. (authors)